No other matters or circumstances have arisen since the end of the nancial year which signicantly affected or may signicantly
affect the operations of the Group or the results of those operations of the Group in future nancial years.
13 July 2018
31 July 2018
8 August 2018
27 August 2018
GMP Certication and Manufacturing Licence Awarded to MXC’s European Facility
The Company’s European medicinal cannabis compounding and manufacturing facility is now fully
GMP certied, and has also been awarded the manufacturing licence for the production of GMP
grade medicinal cannabis based medicines, signifying a major milestone for the Company.
Receipt of formal licence demonstrates the facility complies with strict European production
quality standards during the production process of pharmaceutical grade medicinal cannabis. The
immediate production of pharmaceutical grade medicinal cannabis medicines can now commence.
Neurology & Epilepsy Expert Joins MXC Medical Advisory Board
Associate Professor Wendyl D’Souza has joined the MXC Medical Advisory Board to lead research
and development into medicinal cannabis treatments for Epilepsy and other neurological disorders.
Associate Professor D’Souza is an Authorised Prescriber of Medicinal cannabis and treats over
3,000 patients with drug-resistant epilepsy from currently available treatments in Australia.
Harvey Nichols Expands MGC Derma Distribution into Two New UK Stores
Harvey Nichols has extended sales of the MGC Derma and Derma Plus collections to an additional
two UK stores, tripling the total number of stores and is expected to increase sales accordingly.
Three MGC Derma Anti-Aging creams have also been short-listed for
the Notebook Anti-Aging Beauty Awards providing strong validation of
the products’ efcacy and booting the products’ recognition.
Ethics Approval received for Australian Phase II Clinical Trial into Dementia
In partnership with the Institute for Health Research at the Univertsity of Notre Dame, the
Company has received Human Research Ethics Committee approval to conduct a Phase
II clinical trial into the benets of CogniCannTM in Dementia and Alzheimer patients.
CogniCann™ is one of MXC’s medical cannabis pharmaceutical products with a THC:CBD
ratio specically formulated for the treatment of key Dementia symptoms and improving
specic cognitive functions. The WA based trial is expected to commence in early 2019.
Directors Report
After Reporting
Date Events
15
| Annual Report 2018